Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 103 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Conditions
Ovarian Cancer
Interventions
Olaparib, Ceralasertib, Placebo to match olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more
Conditions
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Conditions
Non-Small Cell Lung Cancer
Interventions
pemetrexed, nivolumab, paclitaxel, veliparib, carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • Whittier, California • Aurora, Colorado + 3 more
Conditions
Breast Neoplasms
Interventions
Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
2
States / cities
West Hollywood, California • Boston, Massachusetts
Conditions
Breast Cancer
Interventions
Sapacitabine, Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Conditions
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions
Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Gastric Cancer
Interventions
Veliparib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 2 more
Conditions
Fibromyalgia
Interventions
D-Ribose Powder, Placebo Powder
Drug · Dietary Supplement
Lead sponsor
RiboCor, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Sacramento, California • DeLand, Florida • Ocala, Florida + 6 more
Conditions
Neuroendocrine Tumors
Interventions
Pasireotide, Sir-sphere Radioembolization, Everolimus
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CoQ10 and D-ribose in Patients With Diastolic Heart Failure

NCT03133793
Conditions
Heart Failure, Diastolic
Interventions
CoQ10, D-Ribose Oral Powder, Placebo pills, Placebo powder
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Fibromyalgia, CFS
Interventions
Smart Energy System
Dietary Supplement
Lead sponsor
Practitioners Alliance Network
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kailua, Hawaii
Conditions
Advanced Solid Tumors
Interventions
AZD2281, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more
Conditions
Ovarian Neoplasms
Interventions
Niraparib, TSR-042, Bevacizumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Conditions
Leukemia
Interventions
Talazoparib, Decitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Ceralasertib, Olaparib, Durvalumab
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Duarte, California • San Francisco, California • Chicago, Illinois
Conditions
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Interventions
Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
38
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more
Conditions
Ovarian Neoplasms
Interventions
AZD2281, Liposomal Doxorubicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Bevacizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more
Conditions
Fatigue
Interventions
D-ribose, Dextrose
Dietary Supplement
Lead sponsor
Bioenergy Life Science, Inc.
Industry
Eligibility
50 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Ovarian Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Vallejo, California • Gainesville, Florida + 10 more
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
47
States / cities
Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more
Conditions
Ovarian Cancer
Interventions
Tuvusertib (M1774), Niraparib, Lartesertib (M4076)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 4 more